In a sea of new multiple myeloma treatment options, Shaji Kumar, M.D., hematologist at Mayo Clinic in Rochester, Minnesota, recommends taking the long view: Both initial and subsequent treatments should be selected bearing in mind what may be coming in the Read more…
Implementing policies and strategies to eliminate racial disparities could improve outcomes for both diseases Income level, employment, housing location, medical insurance, education, tobacco and alcohol use, diet and obesity, access to medical care. These are some of the factors causing Read more…
In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The University of Texas MD Anderson Cancer Center found that men with localized prostate cancer who reported a baseline Read more…
The type and abundance of bacteria found in the mouth may be linked to lung cancer risk in non-smokers, finds the first study of its kind, published online in the journal Thorax. Read More…
A comprehensive study from Uppsala University, involving more than 250,000 women, shows that oral contraceptive use protects against ovarian and endometrial cancer. The protective effect remains for several decades after discontinuing the use. The study is published in the journal Cancer Read more…
Relative to the previous standard of sunitinib, a combination of the checkpoint inhibitor nivolumab and the tyrosine kinase inhibitor cabozantinib improve overall survival (OS) in patients with advanced renal cell carcinoma (RCC), according to results from the phase 3 CheckMate Read more…
The FDA granted accelerated approval to pralsetinib (Gavreto, Blueprint Medicines) for adults with metastatic RET fusion–positive non-small cell lung cancer (NSCLC) detected by an FDA-approved test. “Targeted therapies have dramatically improved care for patients with non-small cell lung cancer driven by oncogenes, Read more…
The FDA approved relugolix (Orgovyx, Myovant Sciences), the first oral androgen deprivation therapy for adults with advanced prostate cancer. As the first oral drug in this class, relugolix may reduce or eliminate the need for some patients “to visit the Read more…
Cancer drugs represented the lion’s share of new drug approvals in 2020, with 21 novel agents expected to be approved. In a presentation at the AMCP Nexus 2020 Virtual meeting, Aimee Tharaldson, PharmD, a senior clinical pharmacist in emerging therapeutics Read more…
The FDA approved new indications for olaparib (Lynparza, AstraZeneca) and bevacizumab-awwb (Mvasi, Amgen) to be used in combination for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Read More…